Jill Barton
General Practice · Canfield, OHNPI 1922149103
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,697 of the $48,067 with a category attached, or 82.6%. 39 manufacturers reported payments, led by Insulet Corporation at 59.4% of the total. 2025 is the largest year on record at $21,396, more than ten times the $33 reported in 2019. Among general practice clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $81.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$29K
- Tandem Diabetes Care, Inc.$12K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$691
- Abbott$662
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$39,69783%
- Travel & lodging$3541%
- Food & beverage$8,01317%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 87 | $28,543 |
| Tandem Diabetes Care, Inc. | 17 | $11,611 |
| Lilly USA, LLC | 103 | $1,452 |
| Novo Nordisk | 78 | $1,013 |
| AbbVie | 55 | $691 |
| Abbott | 32 | $662 |
| Dexcom, Inc. | 22 | $579 |
| Boehringer Ingelheim | 29 | $448 |
| Bayer | 14 | $279 |
| Corcept Therapeutics | 14 | $264 |
| AstraZeneca | 14 | $222 |
| Sanofi-aventis U.S. LLC | 11 | $214 |
| Medtronic | 5 | $177 |
| Novartis | 9 | $171 |
| Xeris Pharmaceuticals, Inc. | 9 | $167 |
| Antares Pharma, Inc. | 9 | $155 |
| Recordati_rare_diseases_inc. | 7 | $149 |
| Ascendis Pharma Endocrinology Inc | 6 | $141 |
| Amarin Pharma, Inc. | 18 | $131 |
| Amgen | 7 | $125 |
| Pfizer | 4 | $124 |
| Amneal Pharmaceuticals LLC | 4 | $94 |
| IBSA Pharma Inc. | 5 | $88 |
| Kyowa Kirin, Inc. | 3 | $71 |
| Verity Pharmaceuticals Inc. | 3 | $64 |
| Ascensia Diabetes Care US Inc. | 1 | $53 |
| Sequel Med Tech, LLC | 2 | $49 |
| Clarus Therapeutics Inc. | 4 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Mannkind Corporation | 1 | $34 |
| Cequr Corporation | 1 | $33 |
| Chiesi USA, Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| EUSA Pharma (US) LLC | 2 | $31 |
| Intrabio Inc | 1 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$28,092
- t:slim X2 Insulin Pump with Control-IQ$11,575
- DEXCOM G6 TRANSMITTER$120
- FreeStyle Libre$108
How this compares
$48,067 in reported general payments places this provider in the 95th percentile of 2,933 general practice providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 142 | $281,597 |
| MounjaroTirzepatide | 106 | $115,178 |
| TrulicityDulaglutide | 56 | $84,960 |
| JardianceEmpagliflozin | 66 | $83,261 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $61,011 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $56,872 |
| FarxigaDapagliflozin Propanediol | 43 | $42,783 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $30,492 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $29,755 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $23,117 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 38 | $21,438 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $21,271 |
| Humalog Kwikpen U-100Insulin Lispro | 52 | $20,810 |
| JanuviaSitagliptin Phosphate | 11 | $16,467 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $16,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,013 | $286,212156 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,452 | $211,772202 claims |
| Boehringer IngelheimJardiance | $448 | $83,26166 claims |
| AstraZenecaFarxiga | $222 | $42,78343 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $214 | $26,10433 claims |
| AbbVieSynthroid | $691 | $3,28557 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $94 | $3,006235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,933 general practice providers in Ohio.
Other general practice in Canfield
- Corey RaymondSalem$288K
- Heather PetroffBroadview Heights$170K
- Megan WeisenbergerCincinnati$81K
- Lundon AlbrechtMentor$77K
- Daniel WardColumbus$68K
- Ankur GuptaNorth Ridgeville$67K
- Andrew SmithToledo$44K
- Steven LeungMayfield Hts$35K
- Maria van HuffelGahanna$30K
- Edward CornettBeachwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.